LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

Home・Stock List・Kura Oncology Inc

Kura Oncology Inc

Closed

SectorHealthcare

9.46 -2.17

Buy Sell

Overview

Share price change

24h

Current

Min

8.72

Max

9.65

Key metrics
By Trading Economics
Income	-6.9M -81M
Sales	-3.4M 17M
Profit margin	-467.23
Employees	260
EBITDA	-12M -86M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+190.6% upside

Dividends
By Dow Jones
Next Earnings	6 Aug 2026

Market Stats
By TradingEconomics
Market Cap	89M 844M
Previous open	11.63
Previous close	9.46

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

5.575 / 6.6 Support & Resistance

Kura Oncology Inc Chart

Past performance is not a reliable indicator of future results.

Related News

13 May 2026, 22:54 UTC

Earnings

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

13 May 2026, 23:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13 May 2026, 23:51 UTC

Market Talk

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

13 May 2026, 23:45 UTC

Market Talk

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

13 May 2026, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

13 May 2026, 23:17 UTC

Earnings

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

13 May 2026, 23:16 UTC

Earnings

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

13 May 2026, 23:15 UTC

Earnings

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

13 May 2026, 23:14 UTC

Earnings

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

13 May 2026, 23:02 UTC

Market Talk

Earnings

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

13 May 2026, 22:59 UTC

Market Talk

Earnings

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

13 May 2026, 22:24 UTC

Earnings

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

13 May 2026, 22:23 UTC

Earnings

Xero FY International Organic Revenue Growth 25%>XRO.AU

13 May 2026, 22:23 UTC

Earnings

Xero FY International Revenue Growth 47%>XRO.AU

13 May 2026, 22:22 UTC

Earnings

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

13 May 2026, 22:19 UTC

Earnings

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

13 May 2026, 22:19 UTC

Earnings

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

13 May 2026, 22:18 UTC

Earnings

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

13 May 2026, 22:16 UTC

Earnings

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

13 May 2026, 22:15 UTC

Earnings

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

13 May 2026, 22:15 UTC

Earnings

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

13 May 2026, 22:13 UTC

Earnings

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

13 May 2026, 22:12 UTC

Earnings

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

13 May 2026, 22:11 UTC

Earnings

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

13 May 2026, 22:11 UTC

Earnings

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

13 May 2026, 22:10 UTC

Earnings

Xero Did Not Declare a Dividend>XRO.AU

13 May 2026, 22:10 UTC

Earnings

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

13 May 2026, 22:09 UTC

Earnings

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

13 May 2026, 22:00 UTC

Earnings

Cisco to Shed Jobs for All-In AI Push -- Update

13 May 2026, 21:11 UTC

Earnings

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Peer Comparison

Price change

Kura Oncology Inc Forecast

Price Target

By TipRanks

190.6% upside

12 Months Forecast

Average 28.13 USD 190.6%

High 40 USD

Low 15 USD

Based on 10 Wall Street analysts offering 12 month price targets forKura Oncology Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Based on 10 analysts giving stock ratings to Kura Oncology Inc - Dist in the past 3 months.

Technical Score

By Trading Central

5.575 / 6.6Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.